Loading
companiesCompany
Myriad Genetics
The company that made BRCA testing a business, now selling hereditary panels and the myChoice, EndoPredict and Prolaris tumour tests.
Overview
Myriad held the BRCA1/2 gene patents until the 2013 US Supreme Court ruling and launched BRACAnalysis CDx (2014) and myChoice CDx (2019), the two FDA-approved companion diagnostics for PARP inhibitors. MyRisk is its hereditary cancer panel; EndoPredict (breast) and Prolaris (prostate) are its prognostic tests. Its history is a case study in how gene patents, guidelines and reimbursement shape which tests patients receive.
Headquarters
Salt Lake City, UT, US
Scorecard
All companies#237of 1244 companies, score 21
- approved products +12
- targets +4
- modalities +2
- regions +1
- registry trials +2
2 approved, 0 in phase 3, 0 earlier, 2 targets, 1 registry studies. Formula on the scorecards page.
Type
Diagnostics · MYGN
Stage
Public
Website
Founded
1991
ApprovedGermline BRCA1/2 sequencing companion diagnostic test
BRACAnalysis CDx · BRACAnalysis CDx
The inherited BRCA test that decides who can have PARP inhibitor pills for ovarian, breast, pancreatic and prostate cancer.
ApprovedTumour HRD genomic instability companion diagnostic test
myChoice CDx · myChoice CDx
A tumour test that measures DNA-repair scarring so that women with ovarian cancer beyond BRCA carriers can benefit from PARP inhibitors.
EstablishedGene-expression prognostic assay (12-gene EPclin score)
EndoPredict · EndoPredict
A 12-gene test that combines gene activity with tumour size and lymph nodes to say whether hormone therapy alone is enough, and whether to continue it beyond five years.
EstablishedGene-expression prognostic assay (cell-cycle progression score, prostate)
Prolaris · Prolaris
A gene test on a prostate biopsy that estimates how aggressive the cancer is, to help decide between active surveillance and treatment.
Similar pages
- IdeaAutomatic germline testing for every cancer type where it changes care
Shares Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Germline (hereditary) testing, Ovarian cancer.
- TechnologyRAD51 foci assay (functional HRD test)
Shares HRD genomic scar scores (GIS, LOH, HRDetect), HRD & BRCA testing, Companion diagnostics, Ovarian cancer.
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- TechnologyGene-expression prognostic assays
Shares Prolaris, HR-positive / HER2-negative breast cancer, Prostate cancer.
- TrialPRIMA / ENGOT-OV26
Shares myChoice CDx, HRD genomic scar scores (GIS, LOH, HRDetect), Ovarian cancer.
- TechnologySTRIDE DNA break detection (intoDNA)
Shares HRD genomic scar scores (GIS, LOH, HRDetect), HRD & BRCA testing.
- CompanyintoDNA
Shares HRD & BRCA testing, Ovarian cancer, Prostate cancer.
- CompanyOutcomes4Me
Shares Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer, Prostate cancer.
cancers
fronts
technologies
drugs
ApprovedGermline BRCA1/2 sequencing companion diagnostic test
BRACAnalysis CDx · BRACAnalysis CDx
EstablishedGene-expression prognostic assay (12-gene EPclin score)
EndoPredict · EndoPredict
ApprovedTumour HRD genomic instability companion diagnostic test
myChoice CDx · myChoice CDx
EstablishedGene-expression prognostic assay (cell-cycle progression score, prostate)
Prolaris · Prolaris